https://adisinsight.springer.com/drugsafety/803234240?error=cookies_not_supported&code=8cb3180f-9247-4a40-a762-92f76eaf3061
Regorafenib - AdisInsight
A 69-year-old woman developed hypertension, asthenia, hypothyroidism and diarrhoea [durations of treatments to reaction onsets not stated] during treatment with
regorafenibadisinsight
https://pubmed.ncbi.nlm.nih.gov/28978118/
Regorafenib in combination with silybin as a novel potential strategy for the treatment of...
The present study suggests that silybin in combination with regorafenib is a promising strategy for treatment of metastatic colorectal patients.
https://pubmed.ncbi.nlm.nih.gov/30002715/
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
Over the past ten years, sorafenib, a multikinase inhibitor, has been the only systemic agent approved for first-line treatment of patients with unresectable...
hepatocellular carcinomaregorafeniblatestevidenceclinical
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1472896/full
Frontiers | Case report: Pharmacokinetic interaction involving sirolimus and regorafenib in...
BackgroundSirolimus is primarily metabolized by CYP3A4 and transported by P-gp. Drug interactions that affect this pathway can alter its plasma exposures, re...
case reportfrontierspharmacokineticinteractioninvolving
https://adisinsight.springer.com/drugsafety/803740475?error=cookies_not_supported&code=28511ef0-7820-4dd8-8fd7-46ac842200d9
Regorafenib - AdisInsight
A 62-year-old man developed hand foot syndrome and fatigue during treatment with regorafenib for metastatic colorectal cancer (mCRC). Subsequently, he developed
regorafenibadisinsight
https://adisinsight.springer.com/trials/700364870?error=cookies_not_supported&code=5840301b-284c-4f3f-8e90-f284b6dbc671
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With...
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and
in treatment
https://adisinsight.springer.com/drugsafety/803455335?error=cookies_not_supported&code=fffe67c8-acad-4c47-8fbc-44985ebbcf44
Regorafenib - AdisInsight
A 58-year-old woman developed oral mucositis, vaginal and conjunctival erythema during treatment with regorafenib for metastatic hepatocellular carcinoma.The
regorafenibadisinsight
https://pubmed.ncbi.nlm.nih.gov/33916610/?dopt=Abstract
Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal...
First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has shown some benefit. To accurately identify such patients before...
associated withfirst linetreatment benefitsbiomarkersregorafenib
https://pubmed.ncbi.nlm.nih.gov/27117754/
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal...
Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and the severe toxicities...
clinical outcomeangiogenesisgenotyping